Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Dec;23(12):e165-e166.
doi: 10.1634/theoncologist.2018-0101. Epub 2018 Aug 17.

In Reply

Chau T Dang  1 , Jasmeet C Singh  1 , Richard M Steingart  2 , Anthony F Yu  2
Affiliations
Comment

In Reply

Chau T Dang et al. Oncologist. 2018 Dec.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Zekri J, Abdelghany EM, Abed‐Alsater F. Pertuzumab: Getting the balance right. The Oncologist 2018;23:e164. - PMC - PubMed
    1. Baselga J, Cortés J, Kim SB et al.; CLEOPATRA Study Group . Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109–119. - PMC - PubMed
    1. Baselga J, Swain SM. CLEOPATRA: A phase III evaluation of pertuzumab and trastuzumab for HER2‐positive metastatic breast cancer. Clin Breast Cancer 2010;10:489–491. - PubMed
    1. Swain SM, Baselgag J, Kim SB et al.; CLEOPATRA Study Group . Pertuzumab, trastuzumab, and docetaxel in HER2‐positive metastatic breast cancer. N Engl J Med 2015;372:724–734. - PMC - PubMed
    1. Romond EH, Jeong JH, Rastogi P et al. Seven‐year follow‐up assessment of cardiac function in NSABP B‐31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node‐positive, human epidermal growth factor receptor 2‐positive breast cancer. JClin Oncol 2012;30:3792–3799. - PMC - PubMed